Navigation Links
Novavax Appoints Stanley Erck to Board of Directors
Date:6/26/2009

ROCKVILLE, Md., June 26 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) announced today the appointment of Stanley Erck to the company's Board of Directors. Mr. Erck has more than twenty five years of experience in the biotechnology and health-care industries and served most recently as President and Chief Executive Officer of Iomai Corporation, a developer of vaccines and immune system therapies that was acquired in 2008 by Intercell. Previously, Mr. Erck was President and Chief Executive Officer of Procept, a publicly traded immunology company, Vice President of Corporate Development at Integrated Genetics (now Genzyme), and in management positions at Baxter International. His appointment brings the number of Novavax board members to nine.

John Lambert, Chairman of the Board of Novavax, stated: "We are pleased to have Stanley Erck join our board and bring his pharmaceutical knowledge and many years of experience in vaccine development to our company. He has a strong record of achievement in building successful companies, a keen understanding of the market for infectious disease products and valuable experience in working with public health agencies. We welcome his anticipated contributions to our future success as we expand our pipeline of promising vaccine candidates."

Mr. Erck is also a Director of BioCryst Pharmaceuticals, MaxCyte, Inc. and MdBio Foundation. He received his undergraduate degree from the University of Illinois and his masters in business administration from the University of Chicago.

ABOUT NOVAVAX

Novavax, Inc. (Nasdaq: NVAX) is a clinical-stage biotechnology company creating novel vaccines, including H1N1, to address a broad range of infectious diseases worldwide using advanced proprietary virus-like-particle (VLP) technology. The company produces these VLP-based, potent, recombinant vaccines utilizing new and efficient manufacturing approaches. Additional information about Novavax is available at www.novavax.com and in the company's various filings with the Securities and Exchange Commission.

Forward Looking Statement

Statements herein relating to future financial or business performance, conditions or strategies and other financial and business matters, including expectations regarding revenues, operating expenses, cash burn, and clinical developments and anticipated milestones are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Novavax cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including the Company's ability to progress any product candidates in preclinical or clinical trials; the scope, rate and progress of its preclinical studies and clinical trials and other research and development activities; clinical trial results; current results may not be predictive of future results; even if the data from preclinical studies or clinical trials is positive, the product may not prove to be safe and efficacious; Novavax's pilot plant facility is subject to extensive validation and FDA inspections, which may result in delays and increased costs; our ability to enter into future collaborations with industry partners and the government and the terms, timing and success of any such collaboration; the cost of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; our ability to obtain rights to technology; competition for clinical resources and patient enrollment from drug candidates in development by other companies with greater resources and visibility; our ability to obtain adequate financing in the future through product licensing, co-promotional arrangements, public or private equity or debt financing or otherwise; the maturity of the convertible notes on July 15, 2009; general business conditions; competition; business abilities and judgment of personnel; and the availability of qualified personnel. Further information on the factors and risks that could affect Novavax's business, financial conditions and results of operations, is contained in Novavax's filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov. These forward-looking statements speak only as of the date of this press release, and Novavax assumes no duty to update forward-looking statements.


'/>"/>
SOURCE Novavax, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Preclinical Proof-of-Concept Studies Published for Novavax Seasonal Influenza Virus-Like-Particle Vaccine
2. Novavax CEO to Present at Phacilitate Vaccine Forum Barcelona 2009
3. Novavax and the NIH Agree to Evaluate a Virus-like Particle (VLP) Vaccine Candidate Against the Novel Influenza A (H1N1) Virus
4. Novavax Reports First Quarter 2009 Financial Results
5. Novavax Announces Enrollment in the Second Phase II Study of its Seasonal Influenza VLP Vaccine Candidate
6. Novavax Announces Release Date of 2009 First Quarter, Financial Results and Investor Conference Call
7. Novavax Announces Early Retirement of $17 Million of Convertible Debt
8. NOVAVAX Announces Publication of a Preclinical Study Demonstrating that a Virus-like Particle Vaccine Provided Protection Against Highly Pathogenic H1N1 and H5N1 Influenza Strains
9. Novavax Announces New Capital Infusion Through a Strategic Alliance with Cadila Pharmaceuticals of India
10. Novavax Announces New Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call
11. Novavax Announces Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2017)... ... May 25, 2017 , ... Throughout this webinar, participants will ... process development and economic goals were achieved in both industry and academic settings. ... system, along with techniques for scaling production of mesenchymal stem cells (MSCs) and ...
(Date:5/24/2017)... BOUNTIFUL, Utah (PRWEB) , ... May 24, 2017 ... ... announces the selection and implementation of CLEARAS Water Recovery’s Advanced Biological Nutrient Recovery ... a key component of a $24 million plant upgrade to sustainably meet current ...
(Date:5/24/2017)... May 23, 2017 As Ebola resurfaces in the ... deaths and 20 suspected cases now reported, a new analysis ... database, showed a correlation between the 2014 and 2017 outbreaks ... rose sharply in 2012-13, which preceded the 2014 outbreak. An ... Ebola gene Replikin counts in 2014-15, which again precedes the ...
(Date:5/23/2017)... ... May 23, 2017 , ... Genedata, a ... anniversary, marking the occasion with a strong presence at Bio-IT World Conference & ... further extends an invitation to all attendees to view posters on the ...
Breaking Biology Technology:
(Date:4/5/2017)... 2017  The Allen Institute for Cell Science today ... one-of-a-kind portal and dynamic digital window into the human ... first application of deep learning to create predictive models ... and a growing suite of powerful tools. The Allen ... future publicly available resources created and shared by the ...
(Date:4/3/2017)... April 3, 2017  Data captured by ... platform, detected a statistically significant association between ... to treatment and objective response of cancer ... to predict whether cancer patients will respond ... as well as to improve both pre-infusion potency ...
(Date:3/29/2017)... 2017  higi, the health IT company that operates ... America , today announced a Series B investment ... EveryMove. The new investment and acquisition accelerates higi,s strategy ... transform population health activities through the collection and workflow ... higi collects and secures data today on behalf of ...
Breaking Biology News(10 mins):